Millennium Management LLC Has $1.49 Million Stock Position in Nkarta, Inc. (NASDAQ:NKTX)

Millennium Management LLC increased its stake in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 98.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 600,142 shares of the company's stock after purchasing an additional 298,317 shares during the quarter. Millennium Management LLC owned approximately 0.85% of Nkarta worth $1,494,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its holdings in Nkarta by 138.7% in the 4th quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company's stock valued at $6,319,000 after buying an additional 1,474,560 shares during the period. Wasatch Advisors LP grew its holdings in Nkarta by 37.4% in the 4th quarter. Wasatch Advisors LP now owns 2,520,909 shares of the company's stock valued at $6,277,000 after buying an additional 686,229 shares during the period. Jefferies Financial Group Inc. grew its holdings in Nkarta by 901.7% in the 4th quarter. Jefferies Financial Group Inc. now owns 2,504,219 shares of the company's stock valued at $6,236,000 after buying an additional 2,254,219 shares during the period. Alyeska Investment Group L.P. grew its holdings in Nkarta by 23.0% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,334,696 shares of the company's stock valued at $3,323,000 after buying an additional 250,000 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Nkarta by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 1,181,357 shares of the company's stock valued at $2,942,000 after buying an additional 10,331 shares during the period. Hedge funds and other institutional investors own 80.54% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on NKTX. William Blair reaffirmed a "market perform" rating on shares of Nkarta in a research note on Thursday, May 15th. Needham & Company LLC reduced their price objective on Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Nkarta in a research note on Thursday, March 27th. Finally, Stifel Nicolaus reduced their price target on Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $14.67.

Nkarta Stock Performance

Shares of NASDAQ:NKTX traded up $0.07 during midday trading on Friday, reaching $1.90. The company had a trading volume of 615,328 shares, compared to its average volume of 1,061,349. Nkarta, Inc. has a 1-year low of $1.31 and a 1-year high of $8.23. The firm has a market cap of $134.82 million, a price-to-earnings ratio of -1.01 and a beta of 0.81. The company has a fifty day simple moving average of $1.82 and a two-hundred day simple moving average of $2.08.

Nkarta (NASDAQ:NKTX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.01. Analysts expect that Nkarta, Inc. will post -1.7 EPS for the current year.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.